HK1209284A1 - Pyrimidinyl tyrosine kinase inhibitors - Google Patents

Pyrimidinyl tyrosine kinase inhibitors

Info

Publication number: HK1209284A1
Authority: HK; Hong Kong
Prior art keywords: tyrosine kinase; kinase inhibitors; pyrimidinyl; pyrimidinyl tyrosine; inhibitors
Prior art date: 2012-06-08

Application number

HK15110301.6A

Other languages

English (en)

Chinese (zh)

Inventor

Brian T Hopkins

Patrick Conlon

Timothy R Chan

Tracy J Jenkins

Xiongwei Cai

Michael Humora

Xianglin Shi

Ross A Miller

Andrew Thompson

Original Assignee

Biogen Idec Inc

Sunesis Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-06-08

Filing date

2015-10-20

Publication date

2016-04-01

2015-10-20 Application filed by Biogen Idec Inc, Sunesis Pharmaceuticals Inc filed Critical Biogen Idec Inc

2016-04-01 Publication of HK1209284A1 publication Critical patent/HK1209284A1/xx

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Cardiology (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)

HK15110301.6A 2012-06-08 2015-10-20 Pyrimidinyl tyrosine kinase inhibitors HK1209284A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261657360P	2012-06-08	2012-06-08
PCT/US2013/044800 WO2013185084A1 (en)	2012-06-08	2013-06-07	Pyrimidinyl tyrosine kinase inhibitors

Publications (1)

Publication Number	Publication Date
HK1209284A1 true HK1209284A1 (en)	2016-04-01

Family

ID=49712704

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK15110301.6A HK1209284A1 (en)	2012-06-08	2015-10-20	Pyrimidinyl tyrosine kinase inhibitors

Country Status (30)

Country	Link
US (5)	US9394277B2 (sl)
EP (3)	EP2858499B1 (sl)
JP (6)	JP6214643B2 (sl)
KR (4)	KR20220154850A (sl)
CN (3)	CN104540385B (sl)
AR (1)	AR091273A1 (sl)
AU (5)	AU2013271407B2 (sl)
BR (2)	BR112014030655B1 (sl)
CA (2)	CA3108186A1 (sl)
CY (1)	CY1120638T1 (sl)
DK (1)	DK2858499T3 (sl)
EA (2)	EA201790418A1 (sl)
ES (2)	ES2684268T3 (sl)
HK (1)	HK1209284A1 (sl)
HR (1)	HRP20181294T1 (sl)
HU (1)	HUE039897T2 (sl)
IL (2)	IL235938B (sl)
IN (1)	IN2014DN10576A (sl)
LT (1)	LT2858499T (sl)
MX (2)	MX363672B (sl)
NZ (1)	NZ702715A (sl)
PH (2)	PH12014502699B1 (sl)
PL (1)	PL2858499T3 (sl)
PT (1)	PT2858499T (sl)
RS (1)	RS57978B1 (sl)
SG (2)	SG10201708535UA (sl)
SI (1)	SI2858499T1 (sl)
TW (3)	TWI592406B (sl)
WO (1)	WO2013185084A1 (sl)
ZA (1)	ZA201409255B (sl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR078320A1 (es) *	2009-09-04	2011-11-02	Biogen Idec Inc	Derivados nitrogenados heterociclicos inhibidores de tirosinquinasas de bruton(btk), formulaciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades autoinmunes, inflamatorias y canceres.
US9273028B2 (en)	2010-10-29	2016-03-01	Biogen Ma Inc.	Heterocyclic tyrosine kinase inhibitors
US9353087B2 (en) *	2012-06-08	2016-05-31	Biogen Ma Inc.	Inhibitors of Bruton's tyrosine kinase
AR091273A1 (es)	2012-06-08	2015-01-21	Biogen Idec Inc	Inhibidores de pirimidinil tirosina quinasa
RS57662B1 (sr) *	2013-12-11	2018-11-30	Biogen Ma Inc	Biaril jedinjenja korisna za lečenje humanih bolesti u onkologiji, neurologiji i imunologiji
WO2015151006A1 (en)	2014-03-29	2015-10-08	Lupin Limited	Substituted purine compounds as btk inhibitors
WO2015170266A1 (en)	2014-05-07	2015-11-12	Lupin Limited	Substituted pyrimidine compounds as btk inhibitors
LT3461821T (lt) *	2014-10-24	2020-08-10	Bristol-Myers Squibb Company	Indolo karboksamido junginiai, naudotini kaip kinazės inhibitoriai
CA3031443A1 (en)	2016-07-21	2018-01-25	Biogen Ma Inc.	Succinate of pyrimidinyl derivatives and solid forms thereof as bruton's tyrosine kinase inhibitors
EP3789040A4 (en)	2018-04-27	2022-03-09	ONO Pharmaceutical Co., Ltd.	PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES WITH A COMPOUND WITH BTK INHIBITING ACTIVITY AS AN INGREDIENT
CN113194928A (zh)	2018-07-31	2021-07-30	罗索肿瘤学公司	(s)-5-氨基-3-(4-((5-氟-2-甲氧基苯甲酰胺基)甲基)苯基)-1-(1,1,1-三氟丙-2-基)-1h-吡唑-4-甲酰胺的喷雾干燥的分散体和制剂
BR112021018168B1 (pt)	2019-03-21	2023-11-28	Onxeo	Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
JP2023500906A (ja)	2019-11-08	2023-01-11	インサーム（インスティテュナシオナルドゥラサンテエドゥラルシェルシェメディカル）	キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
US20240100172A1 (en)	2020-12-21	2024-03-28	Hangzhou Jijing Pharmaceutical Technology Limited	Methods and compounds for targeted autophagy
WO2022212893A1 (en)	2021-04-02	2022-10-06	Biogen Ma Inc.	Combination treatment methods of multiple sclerosis
WO2023081715A1 (en)	2021-11-03	2023-05-11	Viracta Therapeutics, Inc.	Combination of car t-cell therapy with btk inhibitors and methods of use thereof
WO2023081709A1 (en)	2021-11-03	2023-05-11	Viracta Therapeutics, Inc.	Vecabrutinib for the treatment of graft-versus-host disease
WO2023110970A1 (en)	2021-12-14	2023-06-22	Netherlands Translational Research Center Holding B.V	Macrocyclic btk inhibitors

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1624A (en) *		1840-06-10		Cooking-stove
US4528138A (en)	1984-06-20	1985-07-09	E. R. Squibb & Sons, Inc.	16-Keto-17-substituted thia-17-alkyl(or alkenyl or alkynyl) androstenes
US4911920A (en)	1986-07-30	1990-03-27	Alcon Laboratories, Inc.	Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr)	1985-10-03	1988-12-02	Merck Sharp & Dohme	Composition pharmaceutique de type a transition de phase liquide-gel
DE69212850T2 (de)	1991-01-15	1997-03-06	Alcon Lab Inc	Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen
US5212162A (en)	1991-03-27	1993-05-18	Alcon Laboratories, Inc.	Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en)	1994-08-17	2001-10-30	The Rockfeller University	Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
PA8474101A1 (es)	1998-06-19	2000-09-29	Pfizer Prod Inc	Compuestos de pirrolo [2,3-d] pirimidina
US6919178B2 (en)	2000-11-21	2005-07-19	Sunesis Pharmaceuticals, Inc.	Extended tethering approach for rapid identification of ligands
KR20030009391A (ko)	2000-03-17	2003-01-29	브리스톨-마이어스 스퀴브 파마 컴파니	기질 금속단백분해효소 및 ＴＮＦ-α의 억제제인 시클릭β-아미노산 유도체
MY145722A (en)	2000-04-27	2012-03-30	Abbott Lab	Diazabicyclic central nervous system active agents
ATE423120T1 (de)	2000-06-26	2009-03-15	Pfizer Prod Inc	Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe
PE20020507A1 (es) *	2000-10-17	2002-06-25	Schering Corp	Compuestos no-imidazoles como antagonistas del receptor histamina h3
US20050143372A1 (en) *	2001-10-30	2005-06-30	Shomir Ghosh	Compounds, pharmaceutical compositions and methods of use therefor
EP1442039A1 (en)	2001-10-31	2004-08-04	Bayer HealthCare AG	Pyrimido (4,5-b) indole derivatives
MXPA05007485A (es)	2003-01-14	2006-01-30	Arena Pharm Inc	Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
CA2542076C (en)	2003-10-14	2013-02-26	Arizona Board Of Regents On Behalf Of The University Of Arizona	Substituted tricyclic compounds as protein kinase inhibitors
WO2006073419A2 (en) *	2004-04-01	2006-07-13	Gang Zheng	Lipoprotein nanoplatforms
EP1750727A2 (en)	2004-04-23	2007-02-14	Exelixis, Inc.	Kinase modulators and methods of use
FR2870541B1 (fr)	2004-05-18	2006-07-14	Proskelia Sas	Derives de pyrimidines antigonistes du recepteur de la vitronectine
TW200621760A (en)	2004-09-09	2006-07-01	Mitsubishi Pharma Corp	2-morpholino-4-pyrimidone compound
AU2005304784B2 (en) *	2004-11-04	2011-03-24	Vertex Pharmaceuticals Incorporated	Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
KR101351209B1 (ko)	2004-12-03	2014-02-06	머크 샤프 앤드 돔 코포레이션	Ｃｂ1 길항제로서 치환된 피페라진
US7994172B2 (en)	2004-12-28	2011-08-09	Exelixis, Inc.	[1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
US7880002B2 (en)	2004-12-29	2011-02-01	Millennium Pharmaceuticals, Inc.	Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
WO2006091450A1 (en) *	2005-02-18	2006-08-31	Lexicon Genetics Incorporated	4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
US20060281700A1 (en)	2005-06-10	2006-12-14	Baumann Christian A	Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20060281764A1 (en)	2005-06-10	2006-12-14	Gaul Michael D	Aminopyrimidines as kinase modulators
TW200740779A (en)	2005-07-22	2007-11-01	Mitsubishi Pharma Corp	Intermediate compound for synthesizing pharmaceutical agent and production method thereof
PL1951684T3 (pl)	2005-11-01	2017-03-31	Targegen, Inc.	Biarylowe meta-pirymidynowe inhibitory kinaz
PE20071162A1 (es) *	2005-12-21	2007-11-30	Schering Corp	Combinacion de un antagonista/agonista inverso de h3 y un supresor del apetito
US20080076924A1 (en)	2006-06-30	2008-03-27	Patrick Betschmann	Piperazines as P2X7 antagonists
WO2008012635A2 (en)	2006-07-26	2008-01-31	Pfizer Products Inc.	Amine derivatives useful as anticancer agents
EP2059305A2 (en)	2006-07-26	2009-05-20	Novartis Ag	Inhibitors of undecaprenyl pyrophosphate synthase
WO2008033858A2 (en) *	2006-09-11	2008-03-20	Cgi Pharmaceuticals, Inc.	Kinase inhibitors, and methods of using and identifying kinase inhibitors
EP2526933B1 (en) *	2006-09-22	2015-02-25	Pharmacyclics, Inc.	Inhibitors of Bruton's tyrosine kinase
CN101674831A (zh) *	2007-03-02	2010-03-17	先灵公司	用于治疗糖尿病或疼痛的哌啶基哌啶和哌嗪基哌啶
EP2125819B1 (en)	2007-03-21	2014-10-22	Bristol-Myers Squibb Company	Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
WO2008144253A1 (en)	2007-05-14	2008-11-27	Irm Llc	Protein kinase inhibitors and methods for using thereof
US20100216779A1 (en)	2007-06-01	2010-08-26	Glaxosmithkline Llc	Imidazopyridine Kinase Inhibitors
EP2242749B1 (en)	2008-02-05	2013-04-10	F. Hoffmann-La Roche AG	Novel pyridinones and pyridazinones
CA2760044A1 (en)	2008-04-29	2009-11-05	Immunexcite, Inc.	Immunomodulating compositions and methods of use thereof
JP5369183B2 (ja)	2008-07-16	2013-12-18	ファーマサイクリックス，インク．	固形腫瘍の治療用のブルートンのチロシンキナーゼの阻害剤
WO2010068788A1 (en) *	2008-12-10	2010-06-17	Cgi Pharmaceuticals, Inc.	Heterocyclic amides as btk inhibitors
WO2010080481A1 (en)	2008-12-19	2010-07-15	Bristol-Myers Squibb Company	Carbazole carboxamide compounds useful as kinase inhibitors
EP3255047B1 (en)	2009-01-06	2021-06-30	Dana-Farber Cancer Institute, Inc.	Pyrimido-diazepinone kinase scaffold compounds and uses in treating disorders
US9096610B2 (en)	2009-05-25	2015-08-04	Sandoz Ag	Method for the production of ceftobiprole medocaril
WO2011029043A1 (en)	2009-09-04	2011-03-10	Biogen Idec Ma Inc.	Heteroaryl btk inhibitors
AR078320A1 (es)	2009-09-04	2011-11-02	Biogen Idec Inc	Derivados nitrogenados heterociclicos inhibidores de tirosinquinasas de bruton(btk), formulaciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades autoinmunes, inflamatorias y canceres.
US8685880B2 (en)	2010-06-30	2014-04-01	Chevron U.S.A. Inc.	On-site drying of aqueous salt for ionic liquid make-up
US9273028B2 (en)	2010-10-29	2016-03-01	Biogen Ma Inc.	Heterocyclic tyrosine kinase inhibitors
US9353087B2 (en)	2012-06-08	2016-05-31	Biogen Ma Inc.	Inhibitors of Bruton's tyrosine kinase
AR091273A1 (es) *	2012-06-08	2015-01-21	Biogen Idec Inc	Inhibidores de pirimidinil tirosina quinasa
RS57662B1 (sr)	2013-12-11	2018-11-30	Biogen Ma Inc	Biaril jedinjenja korisna za lečenje humanih bolesti u onkologiji, neurologiji i imunologiji
US10280169B2 (en)	2013-12-11	2019-05-07	Biogen Ma Inc.	Biaryl bruton's tyrosine kinase inhibitors
US20170298446A1 (en)	2014-10-03	2017-10-19	Ohio State Innovation Foundation	Biomarkers of bruton tyrosine kinase inhibitor resistance

2013
- 2013-06-05 AR ARP130101980 patent/AR091273A1/es not_active Application Discontinuation
- 2013-06-07 JP JP2015516256A patent/JP6214643B2/ja active Active
- 2013-06-07 PT PT13800042T patent/PT2858499T/pt unknown
- 2013-06-07 CN CN201380036869.5A patent/CN104540385B/zh active Active
- 2013-06-07 HU HUE13800042A patent/HUE039897T2/hu unknown
- 2013-06-07 KR KR1020227039393A patent/KR20220154850A/ko not_active Application Discontinuation
- 2013-06-07 CN CN201810384098.3A patent/CN109305959B/zh active Active
- 2013-06-07 CA CA3108186A patent/CA3108186A1/en not_active Abandoned
- 2013-06-07 PL PL13800042T patent/PL2858499T3/pl unknown
- 2013-06-07 KR KR1020207010675A patent/KR20200043497A/ko active Application Filing
- 2013-06-07 EP EP13800042.7A patent/EP2858499B1/en active Active
- 2013-06-07 TW TW102120447A patent/TWI592406B/zh active
- 2013-06-07 KR KR1020157000393A patent/KR102102587B1/ko active IP Right Grant
- 2013-06-07 US US14/406,315 patent/US9394277B2/en active Active
- 2013-06-07 ES ES13800042.7T patent/ES2684268T3/es active Active
- 2013-06-07 KR KR1020217017552A patent/KR102468430B1/ko active IP Right Grant
- 2013-06-07 SG SG10201708535UA patent/SG10201708535UA/en unknown
- 2013-06-07 EP EP20186539.1A patent/EP3753934A1/en active Pending
- 2013-06-07 MX MX2014015044A patent/MX363672B/es unknown
- 2013-06-07 RS RS20180950A patent/RS57978B1/sr unknown
- 2013-06-07 TW TW106116775A patent/TWI719209B/zh active
- 2013-06-07 SI SI201331130T patent/SI2858499T1/sl unknown
- 2013-06-07 EA EA201790418A patent/EA201790418A1/ru unknown
- 2013-06-07 EA EA201492056A patent/EA027823B1/ru unknown
- 2013-06-07 AU AU2013271407A patent/AU2013271407B2/en active Active
- 2013-06-07 LT LTEP13800042.7T patent/LT2858499T/lt unknown
- 2013-06-07 ES ES18171833T patent/ES2834333T3/es active Active
- 2013-06-07 IN IN10576DEN2014 patent/IN2014DN10576A/en unknown
- 2013-06-07 EP EP18171833.9A patent/EP3385263B1/en active Active
- 2013-06-07 TW TW110102365A patent/TWI792158B/zh active
- 2013-06-07 BR BR112014030655-9A patent/BR112014030655B1/pt active IP Right Grant
- 2013-06-07 BR BR122021002178-3A patent/BR122021002178B1/pt active IP Right Grant
- 2013-06-07 DK DK13800042.7T patent/DK2858499T3/en active
- 2013-06-07 SG SG11201408173WA patent/SG11201408173WA/en unknown
- 2013-06-07 WO PCT/US2013/044800 patent/WO2013185084A1/en active Application Filing
- 2013-06-07 CA CA2875799A patent/CA2875799C/en active Active
- 2013-06-07 NZ NZ702715A patent/NZ702715A/en unknown
- 2013-06-07 CN CN202110783143.4A patent/CN113549055A/zh active Pending
2014
- 2014-11-27 IL IL235938A patent/IL235938B/en active IP Right Grant
- 2014-12-03 PH PH12014502699A patent/PH12014502699B1/en unknown
- 2014-12-08 MX MX2019003618A patent/MX2019003618A/es unknown
- 2014-12-15 ZA ZA2014/09255A patent/ZA201409255B/en unknown
2015
- 2015-10-20 HK HK15110301.6A patent/HK1209284A1/xx unknown
2016
- 2016-06-29 US US15/196,389 patent/US9944622B2/en active Active
2017
- 2017-03-07 AU AU2017201536A patent/AU2017201536B2/en active Active
- 2017-08-03 JP JP2017150480A patent/JP2017193583A/ja not_active Withdrawn
2018
- 2018-03-05 US US15/911,546 patent/US10618887B2/en active Active
- 2018-07-09 PH PH12018501463A patent/PH12018501463A1/en unknown
- 2018-08-08 HR HRP20181294TT patent/HRP20181294T1/hr unknown
- 2018-08-16 CY CY181100861T patent/CY1120638T1/el unknown
2019
- 2019-02-04 JP JP2019017850A patent/JP2019077728A/ja not_active Withdrawn
- 2019-05-17 AU AU2019203476A patent/AU2019203476B2/en active Active
2020
- 2020-02-27 US US16/802,959 patent/US20210017155A1/en not_active Abandoned
- 2020-10-11 IL IL277951A patent/IL277951A/en unknown
2021
- 2021-02-08 JP JP2021018127A patent/JP2021073298A/ja active Pending
- 2021-02-08 JP JP2021018128A patent/JP2021073299A/ja active Pending
- 2021-04-21 AU AU2021202412A patent/AU2021202412A1/en not_active Abandoned
2022
- 2022-08-08 US US17/883,202 patent/US20230174511A1/en active Pending
- 2022-11-25 AU AU2022275504A patent/AU2022275504A1/en active Pending
2023
- 2023-01-16 JP JP2023004462A patent/JP2023052415A/ja active Pending

Also Published As

Publication number	Publication date
KR20220154850A (ko)	2022-11-22
EP3753934A1 (en)	2020-12-23
CN113549055A (zh)	2021-10-26
NZ702715A (en)	2016-11-25
PL2858499T3 (pl)	2019-03-29
CN104540385B (zh)	2018-06-05
JP2021073298A (ja)	2021-05-13
PH12018501463A1 (en)	2019-03-04
EA201492056A1 (ru)	2015-05-29
EP2858499B1 (en)	2018-05-16
HUE039897T2 (hu)	2019-02-28
MX2014015044A (es)	2015-09-22
KR20210072139A (ko)	2021-06-16
PT2858499T (pt)	2018-10-24
CN104540385A (zh)	2015-04-22
BR112014030655A2 (pt)	2017-06-27
CN109305959A (zh)	2019-02-05
EP3385263A1 (en)	2018-10-10
JP2023052415A (ja)	2023-04-11
AU2013271407B2 (en)	2016-12-08
JP6214643B2 (ja)	2017-10-18
US9394277B2 (en)	2016-07-19
PH12014502699A1 (en)	2015-02-02
KR20200043497A (ko)	2020-04-27
TWI719209B (zh)	2021-02-21
PH12014502699B1 (en)	2015-02-02
US20190047986A1 (en)	2019-02-14
US20150158843A1 (en)	2015-06-11
DK2858499T3 (en)	2018-08-20
US20210017155A1 (en)	2021-01-21
ES2834333T3 (es)	2021-06-17
KR20150036020A (ko)	2015-04-07
IL235938B (en)	2020-10-29
SG11201408173WA (en)	2015-01-29
CA3108186A1 (en)	2013-12-12
ES2684268T3 (es)	2018-10-02
JP2015518903A (ja)	2015-07-06
CY1120638T1 (el)	2019-12-11
HRP20181294T1 (hr)	2018-10-05
BR112014030655A8 (pt)	2018-01-02
AU2019203476B2 (en)	2021-01-28
AU2021202412A1 (en)	2021-05-20
KR102468430B1 (ko)	2022-11-21
ZA201409255B (en)	2015-12-23
US20230174511A1 (en)	2023-06-08
TW201410668A (zh)	2014-03-16
AU2022275504A1 (en)	2023-01-05
IL235938A0 (en)	2015-02-01
KR102102587B1 (ko)	2020-04-22
IN2014DN10576A (sl)	2015-08-28
EA201790418A1 (ru)	2017-11-30
US9944622B2 (en)	2018-04-17
LT2858499T (lt)	2018-09-10
SG10201708535UA (en)	2017-11-29
AU2017201536A1 (en)	2017-03-23
US10618887B2 (en)	2020-04-14
EP2858499A4 (en)	2016-01-20
US20160304494A1 (en)	2016-10-20
BR112014030655B1 (pt)	2021-04-20
TWI792158B (zh)	2023-02-11
EA027823B1 (ru)	2017-09-29
TWI592406B (zh)	2017-07-21
WO2013185084A1 (en)	2013-12-12
AU2017201536B2 (en)	2019-03-07
EP3385263B1 (en)	2020-07-22
MX2019003618A (es)	2019-07-18
JP2021073299A (ja)	2021-05-13
CN109305959B (zh)	2022-02-08
EP2858499A1 (en)	2015-04-15
AU2013271407A1 (en)	2015-01-22
JP2019077728A (ja)	2019-05-23
RS57978B1 (sr)	2019-01-31
AU2019203476A1 (en)	2019-06-06
MX363672B (es)	2019-03-29
TW202142535A (zh)	2021-11-16
IL277951A (en)	2020-11-30
JP2017193583A (ja)	2017-10-26
SI2858499T1 (sl)	2018-10-30
BR122021002178B1 (pt)	2022-03-22
CA2875799C (en)	2021-03-23
AR091273A1 (es)	2015-01-21
CA2875799A1 (en)	2013-12-12
TW201805279A (zh)	2018-02-16

Publication	Publication Date	Title
IL277951A (en)	2020-11-30	Pyrimidinyls are tyrosine kinase inhibitors
HK1211293A1 (en)	2016-05-20	Brutons tyrosine kinase inhibitors
HK1210775A1 (en)	2016-05-06	Imidazotriazinecarbonitriles useful as kinase inhibitors
HK1212689A1 (zh)	2016-06-17	布魯頓氏酪氨酸激酶抑制劑
HK1249759A1 (zh)	2018-11-09	取代的嘧啶基和吡啶基吡咯並吡啶酮類、其製備方法及其作為激酶抑制劑的用途
HK1208442A1 (en)	2016-03-04	Substituted pyrrolopyrimidinylamino-benzothiazolones as mknk kinase inhibitors mknk
HK1215577A1 (zh)	2016-09-02	蛋白激酶抑制劑
PL2710005T3 (pl)	2017-07-31	Inhibitory kinazy tyrozynowej
GB201211310D0 (en)	2012-08-08	CSF-1R kinase inhibitors
HK1210461A1 (en)	2016-04-22	Inhibitors of brutons tyrosine kinase
HK1206624A1 (en)	2016-01-15	Brutons tyrosine kinase inhibitors for hematopoietic mobilization
HK1209726A1 (en)	2016-04-08	Protein kinase inhibitors
EP2934525A4 (en)	2016-06-08	THIAZOLSUBSTITUTED AMINOPYRIDINE AS MILTSTYROSINKINASE INHIBITOR
HK1205507A1 (en)	2015-12-18	Protein kinase inhibitors
HK1210779A1 (en)	2016-05-06	Inhibitors of brutons tyrosine kinase
PL2634185T3 (pl)	2016-06-30	Inhibitory kinazy TYK2
IL237158A0 (en)	2015-04-30	Amino quinzolines as kinase inhibitors
EP2903970A4 (en)	2016-11-30	SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS
HK1208460A1 (en)	2016-03-04	Protein kinase inhibitors
EP2968331A4 (en)	2016-08-24	PYRROLOPYRIMIDINE COMPOUNDS AS KINASEINHIBITORS
HK1215855A1 (zh)	2016-09-23	酪氨酸蛋白激酶抑制劑
HK1209316A1 (en)	2016-04-01	Substituted picolinamide kinase inhibitors
EP2922823A4 (en)	2016-05-04	PDE10 PYRIMIDININHIBITOREN